Nightstar Announces Closing of Initial Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Ameri...
October 02 2017 - 4:05PM
YASTEST
LEXINGTON, Mass. and LONDON, Oct.
02, 2017 (GLOBE NEWSWIRE) -- Nightstar Therapeutics plc
("Nightstar" or the "Company") (NASDAQ:NITE), a clinical-stage gene
therapy company developing treatments for rare inherited retinal
diseases, today announced the closing of its previously announced
initial public offering in the United States of 6,164,000 American
Depositary Shares ("ADSs") representing 6,164,000 ordinary shares,
at an initial public offering price of $14.00, which includes an
additional 804,000 ADSs issued upon the exercise in full by the
underwriters of their option to purchase additional ADSs.
Aggregate net proceeds to the Company, after underwriting discounts
and commissions and estimated offering expenses payable by the
Company, will be approximately $76.9 million. All of the ADSs were
offered by Nightstar.
Jefferies LLC, Leerink Partners
LLC and BMO Capital Markets Corp. acted as joint book-running
managers for the offering. Wedbush Securities Inc. and Chardan
acted as co-managers.
The offering was made only by
means of a prospectus. A copy of the prospectus relating to
the offering was filed with the U.S. Securities and Exchange
Commission and may be obtained from Jefferies LLC, Attention:
Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd
Floor, New York, NY 10022, or by telephone at (877) 547-6340, or by
email at Prospectus_Department@Jefferies.com; Leerink Partners LLC,
Attention: Syndicate Department, One Federal Street, 37th Floor,
Boston, MA 02110, or by telephone at (800) 808-7525 ext. 6132, or
by email at Syndicate@Leerink.com; or BMO Capital Markets Corp.,
Attention: Equity Syndicate Department, 3 Times Square, New York,
NY 10036, or by telephone at (800) 414-3627, or by email at
bmoprospectus@bmo.com.
A registration statement relating
to these securities has been filed with, and declared effective by,
the U.S. Securities and Exchange Commission. This press
release does not constitute an offer to sell or the solicitation of
an offer to buy securities, and shall not constitute an offer,
solicitation or sale in any jurisdiction in which such offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of that jurisdiction.
About
Nightstar
Nightstar is a leading
clinical-stage gene therapy company focused on developing and
commercializing novel one-time treatments for patients suffering
from rare inherited retinal diseases including choroideremia,
X-linked retinitis pigmentosa and Best vitelliform macular
dystrophy.
Contact:
Senthil Sundaram, Chief Financial
Officer
investors@nightstartx.com
Alicia Davis, THRUST IR
910-620-3302
alicia@thrustir.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Nightstar Therapeutics via Globenewswire
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Mar 2024 to Apr 2024
Nightstar Therapeutics Plc ADS (NASDAQ:NITE)
Historical Stock Chart
From Apr 2023 to Apr 2024